language_icon
EN
HI

Brooks Laboratories Share price

BROOKS

61.3

0.00 (0.00%)
NSE
BSE
Last updated on 22 Apr, 2026 | 15:52 IST
Today's High

63.99

Today's Low

61.00

52 Week Low

36.30

52 Week High

164.02

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Brooks Laboratories Chart

Brooks Laboratories Share Key Metrics

Volume
37303.00
Market Cap
180.57 CR
LTQ@LTP
5@61.30
ATP
62.21
Var Margin
100 %
Circuit Range
58.24-64.36
Delivery %
0 %
Value
23.21 L
ASM/GSM
No
Market Lot
1

Summary

Brooks Laboratories share price stands at ₹61.3 at 22 Apr, 2026 | 15:52. The stock Brooks Laboratories intraday movement has stayed between ₹61.00 and ₹63.99, while on a 52-week basis it has fluctuated from ₹36.30 to ₹164.02.
In terms of trading activity, Brooks Laboratories has recorded a volume of 37303 shares. The Brooks Laboratories has a market cap of ₹29457248. The stock’s Average Traded Price (ATP) stands at ₹6221, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 5, 6130.
The Brooks Laboratories operates within a circuit range of ₹58.24-64.36 – ₹58.24-64.36, with a Value of ₹23.21 L. The Delivery Percentage for the day is 0%. Additionally, Brooks Laboratories currently falls under the No framework, and trades with a market lot size of 1.

Brooks Laboratories Fundamentals

View More
P/E Ratio

8.82

P/B Ratio

1.64

Div. Yield

0

Sector P/E

63.84

Sector P/B

3.48

Sec. Div. Yield

0.57

Brooks Laboratories Resistance and Support

Pivot 62.1

Resistance

First Resistance

63.2

Second Resistance

65.09

Third Resistance

66.19

Support

First Support

60.21

Second Support

59.11

Third Support

57.22

Brooks Laboratories Shareholding Pattern

View More
  • 2016-17
  • 2018-19
  • 2019-20
  • 2020-21
  • 2021-22
  • 2022-23
  • 2023-24
  • 2024-25
  • 2025-26
  • 2026-27
Total Promoters
Segment
Percent

Total Promoters

52.62%

Mutual Fund

9.9%

Insurance

0%

Foreign Institutional Investors

0.17%

Domestic Institutional Investors

0%

Retail

37.32%

Others

-0.01%

Total Promoters
MAR '26
52.62%

Brooks Laboratories Corporate Actions

DateAgenda
2025-08-13Quarterly Results
2025-05-28Audited Results

Brooks Laboratories News

Brooks Laboratories Limited

Brooks Laboratories promoter Atul Ranchal disclosed that no new encumbrances were made by the promoter group during FY26. This confirms compliance with SEBI regulations regarding share acquisitions and takeovers.
Apr 08 2026 11:04:00

Brooks Laboratories Ltd - 533543 - Reply To Clarification Sought Vide Email Dated 1St April 2026 With Reference To Price Movement.

Brooks Laboratories responded to BSE's query on price movement, stating no pending Unpublished Price Sensitive Information. The company emphasized that share price fluctuations are purely market driven and it continues to adhere to all Listing Regulations.
Apr 02 2026 11:04:00

Brooks Laboratories Limited

Brooks Laboratories clarified to NSE that recent share price movements are purely market-driven. The company confirmed no undisclosed material information (UPSI) exists that could impact the stock's price or volume behavior.
Apr 02 2026 11:04:00
Read More

About Brooks Laboratories

NSE : 25140  
BSE : 533543  
ISIN : INE650L01011  

Our Company was incorporated vide a Certificate of Incorporation dated January 23 2002 bearing CIN No. U24232PB2002PLC24910 under the Companies Act 1956 with the name ?Brooks Laboratories Limited? by our promoters Mr. Atul Ranchal & Mr. Rajesh Mahajan. We received our certificate of commencement of business on February 19 2002 from the Registrar of Companies Punjab Himachal Pradesh & Chandigarh at Jalandhar. Our Company was initially promoted for manufacturing of latest molecules in Injectables tablets and dry syrups for the domestic customers. Our Company set up a facility for manufacturing Tablets Dry Syrup and Injectables which was supported by a research and development ("R&D") centre at Baddi Himachal Pradesh. Our Company started its commercial production in the month of June 2006. Our Company became profitable from the very first year of its production. This facility at Baddi is WHO-GMP and ISO 9001:2008 certified. The facility focuses on developing latest molecules in the niche segments and then selling it to various pharmaceutical marketing Companies. Before staring our company our promoters were engaged in manufacturing of Pharmaceutical Formulations in their partnership firm namely Brooks Pharmaceuticals. The firm had a manufacturing facility at F-94 Industrial Area Phase 7 Mohali Punjab. The factory at Mohali had annual installed capacity of 30 Lacs Injectables 300 Lacs Tablets and 15 Lacs Dry Syrups. Our promoters had a successful track record of running the manufacturing of formulations in the aforesaid firm profitably for over 6 years. In order to take an advantage of the growing market and avail the tax and other benefits that were made available by the Government to set up a manufacturing facility at Baddi our promoters decided incorporate our company Brooks Laboratories Ltd and set up a bigger and more sophisticated unit at Baddi in Himachal Pradesh. Subsequently the firm was dissolved in the month of December 2008. Further in years 2007 and 2008 to have a smooth transition from Brook Pharmaceuticals to Brooks Laboratories Ltd. Our Company paid/settled some dues to Creditors and Lenders of Brooks Pharmaceuticals aggregating to Rs. 151.79 Lacs. Later on to settle the above our Company purchased on book value certain assets (Fixed assets & Stocks) aggregating to Rs. 113.27 Lacs and received an aggregate sum of Rs. 38.52 Lacs from M/s. Brooks Pharmaceuticals a partnership firm promoted by our Promoters Mr. Atul Ranchal and Mr. Rajesh Mahajan. Key Events and Milestones January 23 2002Incorporation of Brooks Laboratories Limited. February 192002Received certificate for commencement of business May 5 2005Commenced setting up of manufacturing facility at Baddi Himachal Pradesh. April 102006 Manufacturing drugs license issued by the State Drugs Controlling and Licensing Authority HP. April 30 2005Commissioning of R&D centre at Baddi May 202006 Completion of Commissioning of plant for manufacture of Tablets capsules Injections Oral Liquids etc.May 30 2006Start of commercial production June 1 2006First PPI Formulation developed by the Company. October 272006 Obtained Import license from Drugs Controller General of India under the Drugs Act 1940 and Drugs Rules. August 02 2007 Received an AS/NZS ISO 9001:2000 Certificate from SAI Global Certification Services Pty Limited Australia. April 30 2008* Takeover of some of the Assets of M/s Brooks Pharmaceuticals a partnership firm of Our Promoters Mr. Atul Ranchal & Mr. Rajesh Mahajan by our Company. December 30 2008 Dissolution of M/s Brooks Pharmaceuticals a partnership firm of Our Promoters Mr. Atul Ranchal & Mr. Rajesh Mahajan. January 062009 Micro Small Medium Enterprise (MSME) Registration Certificate issued by Directorate of Industries for Manufacturing/Assembling Injections Capsules & Tabulates (Single Window Clearance Agency). April 72010 The manufacturing facility at Baddi was certified as WHO GMP compliant by Department of Health & Family Welfare HP. July 272010 Received an ISO 9001:2008 Certificate from UKAS Quality Management URS & IAF.

Read More

Brooks Laboratories Management

NamePosition
Krutika Mohan RaneCompany Secretary & Compliance Officer
Bhushan Singh RanaWhole Time Director
View More

Brooks Laboratories FAQs

The Buying Price of Brooks Laboratories share is 61.3 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy Brooks Laboratories stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Brooks Laboratories, choose your preferred order type, and place the trade.

The Price-to-earnings (P/E) ratio of Brooks Laboratories shares is 8.82. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio Brooks Laboratories shares is 1.64. Useful to assess the stock's value relative to its book value.

To assess Brooks Laboratories’s valuation compare Sector P/E, P/B which are 63.84 & 3.48 with sector averages, along with growth rates and financial metrics.

The Market Cap of Brooks Laboratories is 180.57 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of Brooks Laboratories share price is 164.02 & 36.30. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Brooks Laboratories belongs to the Healthcare sector.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost